Egle Therapeutics
Seedtable Score
52
Startups
1
Funding Rounds
1
Investors
$46.22m
Money raised
Overview
Egle Therapeutics, based in Paris, is developing advanced immunotherapies for cancer and autoimmune diseases. Unlike traditional treatments, which often have severe side effects and limited effectiveness, Egle's approach aims to offer better outcomes with fewer side effects. By targeting immune system mechanisms, Egle can potentially transform patient experiences and increase survival rates. Their B2B model, supported by investors like Bioqube Ventures, positions them to form strategic partnerships and secure resources for growth, making them a promising contender in health tech.
- Website: https://egle-tx.com
- Business model: b2b
- Company size: 11 - 51 employees
- Headquarters: Paris, France
- Founded: 2020
- Social accounts: Linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Investors (1)
Funding
Funding series
Funding Series Analysis
The company Egle Therapeutics has raised a total of $46.22m in funding over 1 rounds.
Key Insights:
- Unknown: $46.22m
Egle Therapeutics Unknown (2021, $46M)
$46.22m